Core Insights - Femasys Inc. has made significant progress in clinical, regulatory, and commercial milestones for its FemBloc and FemaSeed products, with ongoing enrollment in the pivotal FINALE clinical trial for FemBloc aimed at U.S. FDA approval [3][5] - The company reported a 40.8% increase in sales for 2025, primarily driven by FemBloc, and has sufficient cash to fund operations into the third quarter of 2026 [6][7] Corporate Highlights - Initiated patient enrollment in the FINALE pivotal clinical trial for FemBloc, a key step toward U.S. approval [5] - Expanded FemaSeed commercialization in the U.S. with the introduction of the FemSperm product family [3] - Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors to strengthen leadership [5] - Achieved certification for FemBloc under the Medical Device Single Audit Program (MDSAP) [5] - Received approval for a new Category III CPT code for FemaSeed, supporting future reimbursement pathways [5] - Entered a strategic distribution partnership with OR Consulting for product launches in Switzerland [5] - Established a partnership with Refuah Health Center to advance FemaSeed adoption in community-based care [5] - Secured FDA 510(k) clearance for the FemVue Controlled device [5] - Completed $12 million financing to strengthen the balance sheet [5] - Initiated a European post-market surveillance study for FemBloc [5] Financial Results - Sales increased by $664,205 to $2,293,313 in 2025 from $1,629,108 in 2024 [6] - Research and development expenses decreased by $638,839 to $7,577,704 in 2025 compared to $8,216,543 in 2024 [6] - Net loss for 2025 was $18,627,887, or ($0.47) per share, compared to a net loss of $18,816,628, or ($0.85) per share in 2024 [6][15] - Cash and cash equivalents as of December 31, 2025, were approximately $9.3 million, with an accumulated deficit of approximately $145.8 million [6][7] Product and Market Information - FemBloc is the first non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [17] - FemaSeed is a first-line infertility treatment that has demonstrated more than double the pregnancy rate of traditional IUI [16][17] - The FemSperm product line enables in-office sperm preparation and analysis for infertility treatment [3][16]

Core Insights - Fortress Biotech, Inc. has achieved significant milestones in 2025 and early 2026, including the FDA approval of ZYCUBO for Menkes disease and the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, demonstrating the company's ability to monetize its assets and advance its portfolio [2][5][12] Regulatory Updates - ZYCUBO (copper histidinate) received FDA approval in January 2026 for treating Menkes disease in pediatric patients [5] - The approval was followed by the sale of the Rare Pediatric Disease Priority Review Voucher by Cyprium Therapeutics for gross proceeds of $205 million [5] Monetization Updates - Checkpoint Therapeutics was acquired by Sun Pharma for approximately $355 million, with Fortress receiving about $28 million upfront and potential future payments including a 2.5% royalty on net sales of UNLOXCYT™ [4][6] - Fortress expects to receive at least $100 million from Cyprium through future dividends and intercompany agreements [5] Financial Performance - Fortress reported consolidated net revenue of $63.3 million for the full year ended December 31, 2025, an increase from $57.7 million in 2024 [12][20] - The company incurred a consolidated net loss attributable to common stockholders of $(1.9) million, or $(0.07) per share, for 2025, compared to a net loss of $(55.9) million, or $(2.69) per share, in 2024 [12][20] Clinical Updates - Crystalys Therapeutics announced a $205 million Series A financing to support Phase 3 clinical studies for dotinurad, with Fortress holding a 3% royalty on future net sales [9][10] - Emrosi™, developed by Journey Medical, reported net product revenues of $61.2 million for 2025, up from $55.1 million in 2024 [7][12]

Exceeds All Financial Guidance MetricsACV as of January 31, 2026, $602.4M, up 17% Year-Over-YearFiscal 2026 ACV Net Retention Rate of 112%Announces $100M Accelerated Share Repurchase Program WILMINGTON, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced financial results for the fourth quarter and fiscal year 2026, ended January 31, 2026. “Fiscal 2026 was a landmark year for nCino, with both the fourth qu ...

Group 1 - The 2026 Annual Shareholder Meeting of Howard Hughes Holdings (HHH) will be held on September 17, 2026, in New York City, instead of June as originally planned [1][2] - Executive Chairman Bill Ackman and Chief Investment Officer Ryan Israel will present on the acquisition of Vantage Group Holdings, which is expected to close in Q2 2026 [1][2] - The meeting will include a Q&A session with CEO David O'Reilly, and is open to the public with advance registration required, prioritizing HHH stockholders [2] Group 2 - Bill Ackman emphasized that the acquisition of Vantage will combine its insurance expertise with Pershing Square's investment capabilities, aiming to create a large, profitable insurance company and long-term value for shareholders [2] - Howard Hughes Holdings focuses on growing long-term shareholder value through its real estate platform, owning and managing various commercial, residential, and mixed-use properties across the U.S. [3]

MONTREAL, March 31, 2026 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported net income attributable to common shareholders of $149.3 million or $61.40 per share for the year ended December 31, 2025. This compares to a net income attributable to common shareholders of $258.1 million or 105.06 per share for the same period in 2024 Financial statements are available online at Sedar+ www.sedarplus.ca CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions of dollars, except per share amounts) For the ...

Core Insights - Tvardi Therapeutics is advancing its clinical pipeline with two significant milestones expected in 2026: topline data from a healthy volunteer study of TTI-109 in Q2 and topline data from a Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H2 [1][3] Financial Performance - Research and development expenses for Q4 2025 were $5.5 million, down from $8.6 million in Q4 2024, while total R&D expenses for 2025 were $18.0 million compared to $23.7 million in 2024 [4] - General and administrative expenses for Q4 2025 were $2.1 million, slightly down from $2.2 million in Q4 2024, but increased for the full year to $8.7 million from $4.5 million in 2024 due to higher professional fees related to the merger with Cara Therapeutics [7] - The net loss for Q4 2025 was $7.3 million, an improvement from a net loss of $12.7 million in Q4 2024, with a full-year net loss of $18.2 million compared to $29.4 million in 2024 [8][9] Cash Position - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $30.8 million, a slight decrease from $31.6 million in 2024, with the company expecting this cash runway to fund operations through Q4 2026 [10] Clinical Trials and Data - The ongoing healthy volunteer study of TTI-109 is expected to yield topline data in Q2 2026, while the Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 will report topline results in the second half of 2026 [5][4] - Interim results from the REVERT IPF Phase 2 trial indicated a 9.4% reduction in fibrosis score for TTI-101 compared to 2.4% for placebo, alongside a 4.5-fold greater decline in IL-6 levels [4]

Core Insights - Jushi Holdings Inc. reported a total revenue of $262.9 million for the full year 2025, reflecting a 2% increase year-over-year, driven by contributions from new store openings [1][6] - The company achieved operational improvements in 2025, enhancing cultivation performance and product availability [1][8] - Jushi refinanced its debt post year-end, extending maturities to 2029, which improved liquidity and strengthened the balance sheet [1][7] Financial Highlights - For Q4 2025, total revenue was $68.3 million, with a gross profit of $28.6 million and a gross profit margin of 41.9% [6][9] - The net loss for Q4 2025 was $15.6 million, while adjusted EBITDA was $13.9 million, resulting in an adjusted EBITDA margin of 20.4% [6][9] - For FY 2025, the gross profit was $114.0 million, with a gross profit margin of 43.4%, despite a net loss of $68.6 million [6][9] Operational Developments - Jushi expanded its retail footprint with eight new store openings, ending the year with 42 operating dispensaries across eight states [6][10] - The company introduced 280 new unique SKUs across its product portfolio, indicating continued innovation [6][10] - Jushi-branded products accounted for 58% of retail revenue, an increase of 332 basis points year-over-year [6][12] Market and Legislative Context - Virginia's adult-use cannabis legislation was passed, establishing a regulated retail market with sales expected to begin on January 1, 2027, pending the Governor's approval [1][8] - The company is positioned to benefit from the anticipated expansion of the cannabis market in Virginia due to its existing infrastructure [8][10] Balance Sheet and Liquidity - As of December 31, 2025, Jushi had approximately $26.6 million in cash and cash equivalents, with total debt of $207.8 million [14][29] - The refinancing of existing loans was completed through a $160.0 million secured term loan, enhancing financial flexibility [7][14] Shareholder Information - As of March 24, 2026, the company had 199,696,597 issued and outstanding shares, with fully diluted shares outstanding at 305,631,936 [15]

Core Insights - Arcutis Biotherapeutics, Inc. is set to present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, with a fireside chat scheduled for April 14, 2026, at 11:00 am ET [1] Company Overview - Arcutis is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases [2] - The company utilizes a unique dermatology development platform and expertise to create differentiated therapies targeting biologically validated areas, resulting in a robust pipeline for various inflammatory dermatological conditions [2]

Group 1 - EDF filed its Universal Registration Document for the 2025 financial year with the French financial markets' authority [1] - The Universal Registration Document includes the Annual Financial Report, Board of Directors' report, corporate governance details, vigilance plan, sustainability information, and statutory auditors' reports [4] - The document is available on EDF's website in compliance with regulatory requirements [1] Group 2 - EDF is a key player in the energy transition, operating in power generation, distribution, trading, energy sales, and services [2] - The company is a world leader in low-carbon energy, generating 515 TWh of electricity with 95% decarbonization and a carbon intensity of 26.5 gCO2/kWh in 2025 [2] - EDF serves approximately 41 million customers and reported consolidated sales of €113.3 billion in 2025 [2]

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has made significant advancements in its operations and strategic positioning during 2025, including management changes, capital raising, and progress in clinical trials for its lead compound, LB-100 [2][3]. Group 1: Company Overview - LIXTE is a clinical-stage pharmaceutical and med-tech company focused on developing cancer therapies, particularly through its lead compound, LB-100, which is a first-in-class PP2A inhibitor [5]. - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, with ongoing clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [5]. Group 2: Management and Board Changes - Geordan Pursglove was appointed as Chairman and CEO in June 2025, with a new management team and board members added to strengthen the company's leadership [6]. - The former CEO, Bas van der Baan, transitioned to Chief Scientific Officer, while Peter Stazzone was named Chief Financial Officer [6]. Group 3: Financial Highlights - The company successfully raised over $11 million through two registered direct offerings and a private placement, which will be used for general corporate purposes and working capital [6]. - The relocation of the corporate headquarters to Boca Raton is part of the company's strategic initiatives [6]. Group 4: Clinical and Strategic Developments - LIXTE expanded its clinical trial for LB-100 in collaboration with the Robert H. Lurie Comprehensive Cancer Center, increasing patient enrollment from 21 to 42 [6]. - A strategic acquisition of Liora Technologies Europe Ltd. was completed, which includes the LiGHT System for electronically controlled proton therapy, expected to enhance treatment options for various cancers [6][7].